Deargen Signs Agreement With Sookmyung Women s University Research & Business Development Foundation for Licensing NASH Biomarker Technologies | Business cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
Search jobs 05-May-2021 Takara Bio Europe AB and PanCryos Announce Licensing Agreement to Enable Development of Cell-Based Therapy for Diabetes
Göteberg, Sweden May 05, 2021
Life Science Newswire – Takara Bio Europe AB (TBEAB) and PanCryos are pleased to announce that they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEAB’s new out-licensing program, which enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications. Jacqueline Ameri, CEO of PanCryos said, “We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will
Published: Apr 01, 2021
MOUNTAIN VIEW, Calif. (BUSINESS WIRE) Takara Bio USA, Inc.., a wholly owned subsidiary of Takara Bio Inc., is collaborating with Indiana University of Pennsylvania (IUP), and Indiana Regional Medical Center (IRMC) to enable better and faster COVID-19 testing for rural communities in the United States and around the world.
Many rural communities have been struggling to keep up with the demand for COVID-19 testing. Although medical and laboratory personnel are doing their best to process samples, current detection protocols are expensive and slow, and they can expose laboratory personnel to the novel coronavirus (SARS-CoV-2). Furthermore, underserved communities have been hit especially hard by supply chain issues with sample processing components.
Share this article
Share this article
PALO ALTO, Calif., March 12, 2021 /PRNewswire/ HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell s Single Cell Dispensers and Takara Bio s SMART-seq® kits to characterize HepaTx s novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes.